Background: Previous studies demonstrated that selenite induced cancer-cell apoptosis through multiple mechanisms; however, effects of selenite on microtubules in leukemic cells have not been demonstrated. Methods: The toxic effect of selenite on leukemic HL60 cells was performed with cell counting kit 8. Selenite effects on cell cycle distribution and apoptosis induction were determined by flow cytometry. The contents of cyclin B1, Mcl-1, AIF, cytochrome C, insoluble and soluble tubulins were detected with western blotting. Microtubules were visualized with indirect immunofluorescence microscopy. The interaction between CDK1 and Mcl-1 was assessed with immunoprecipitation. Decreasing Mcl-1 and cyclin B1 expression were carried out through siRNA interference. The alterations of Mcl-1 and cyclin B1 in animal model were detected with either immunohistochemical staining or western blotting. In situ detection of apoptotic ratio was performed with TUNEL assay. Results: Our current results showed that selenite inhibited the growth of HL60 cells and induced mitochondrial-related apoptosis. Furthermore, we found that microtubule assembly in HL60 cells was altered, those cells were arrested at G2/M phase, and Cyclin B1 was up-regulated and interacted with CDK1, which led to down-regulation of the anti-apoptotic protein Mcl-1. Finally, in vivo experiments confirmed the in vitro microtubule disruption effect and alterations in Cyclin B1 and Mcl-1 levels by selenite. Conclusions: Taken together, the results from our study indicate that microtubules are novel targets of selenite in leukemic HL60 cells.
Background: Serum lactate dehydrogenase to albumin ratio (LAR) is a newly discovered indicator that can comprehensively reflect the inflammatory or nutritional status of the body and has been proven to be associated with several diseases. This study aimed to investigate whether a high baseline LAR independently predicts worse prognosis in non-small cell lung cancer (NSCLC) patients undergoing radical surgery. Methods: This study retrospectively reviewed NSCLC patients who received radical surgery between January 2019 and October 2021 in our institution. Then, these patients were further categorized into low LAR and high LAR groups using X-tile software. Both univariate and multivariate logistic regression analyses were utilized to identify independent predictors of disease-free survival (DFS). A paired t -test was conducted to evaluate the changes in LAR after surgery. Results: A total of 233 patients were enrolled in this study. Patients with high baseline LAR had significantly worse DFS ( P < 0.001) than those with low baseline LAR. According to Cox regression analysis, baseline LAR [hazard ratio (HR) 2.25, 95% confidence interval (CI) 1.01–5.01, P = 0.046] and tumor staging (HR 0.15, 95% CI 0.07–0.33, P < 0.001) were identified as independent predictors for DFS. Besides, based on the data of 97 patients who underwent their first follow-up at our hospital, cases with stage II/III tumors showed a significant decrease in LAR after surgery ( P < 0.05), whereas no significant change was observed in stage I patients ( P = 0.23). Conclusion: LAR emerged as a potential prognostic indicator for operable NSCLC patients. Cases with higher baseline LAR levels tend to have a poorer prognosis.